The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Recovery, Persistence, and Sequelae in Hepatitis C Virus Infection: A Perspective on Long-Term Outcome
Open accessAbstract
Hepatitis C has emerged in recent years as the most common basis for liver disease in the United States, having infected an estimated 3.9 million people in this country and an estimated 170 million worldwide.Currently, it is the predominant reason for undergoing liver transplantation.The disease it causes is characterized by silent onset in most infected individuals, a high rate of viral persistence, and the potential for development of everworsening chronic liver disease, ranging from chronic hepatitis to cirrhosis and occasionally to hepatocellular carcinoma.Such progression, when it occurs, is also most commonly a silent process that may take 20-40, and occasionally even more, years to reach its end point.Because of these characteristics, it has been exceedingly difficult to accurately assess the natural history.Efforts to accomplish this have consisted of retrospective, prospective, and cohort studies.The most concerning data have derived from the retrospective study approach, generally performed at tertiary referral centers.Because these centers commonly attract persons with existing chronic liver disease, they have tended to describe a high rate of progression to cirrhosis and cancer.This "referral bias" is avoided in the prospective and cohort study approach, and data derived from these studies indicate a lower rate of progression and a correspondingly higher rate of either recovery or minimal liver disease.In this review, we briefly describe potential mechanisms of viral persistence; present detailed information on outcomes that have derived from retrospective, prospective, and cohort studies, involving both adults and children; examine the data regarding progression of fibrosis and of progression to hepatocellular carcinoma; consider cofactors that might enhance liver disease progression; and report the emerging data that suggest that spontaneous viral clearance may be higher than is currently believed.We conclude with the view that severe, life-threatening, progressive liver disease clearly occurs in a sizable minority (perhaps 30%) of chronically infected persons but speculate that fibrosis progression is neither linear or inevitable and hence that most hepatitis C virus carriers will have either a stable nonprogressive course or such indolent pro-Objectives Upon completion of this article, the reader should recognize: 1) the influence of study design on estimates of HCV disease severity; 2) that the rate of spontaneous recovery from HCV infection is higher than previously considered; 3) that fibrosis progression is not linear and is influenced by cofactors, particularly alcohol; 4) that it is likely that the majority of HCV infected individuals will not develop cirrhosis or other life threatening complications of their infection; and 5) that although the individual risk of developing severe complications may be less than 30%, the societal burden of HCV infection is very high because of the high prevalence and global distribution of the agent. AccreditationThe Indiana University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.The Indiana University School of Medicine takes responsibility for the contents, quality, and scientific integrity of this activity. CreditThe Indiana University School of Medicine designates this educational activity for a maximum of 1.0 hours credit toward the AMA Physicians Recognition Award in category one.Each physician should claim only those hours of credit that he/she actually spent in the educational activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Isolation of a cDNA cLone Derived from a Blood-Borne Non-A, Non-B Viral Hepatitis Genome
Choo, Q.-L., Kuo, G., Weiner, A. J., Overby, L. R., Bradley, D. W., & Houghton, M. (1989) · Science · doi:10.1126/science.2523562 · Cited by 6,875
McHutchison, J. G., Gordon, S. C., Schiff, E. R., Shiffman, M. L., Lee, W. M., Rustgi, V. K., Goodman, Z. D., Ling, M.-H., Cort, S., & Albrecht, J. K. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811193392101 · Cited by 3,465
Natural history of liver fibrosis progression in patients with chronic hepatitis C
Poynard, T., Bedossa, P., & Opolon, P. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07642-8 · Cited by 3,011
The Prevalence of Hepatitis C Virus Infection in the United States, 1988 through 1994
Alter, M. J., Kruszon-Moran, D., Nainan, O. V., McQuillan, G. M., Gao, F., Moyer, L. A., Kaslow, R. A., & Margolis, H. S. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908193410802 · Cited by 2,992
The Natural History of Community-Acquired Hepatitis C in the United States
Alter, M. J., Margolis, H. S., Krawczynski, K., Judson, F. N., Mares, A., Alexander, W. J., Hu, P. Y., Miller, J. K., Gerber, M. A., Sampliner, R. E., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199212313272702 · Cited by 1,592
Fattovich, G., Giustina, G., Degos, F., Tremolada, F., Diodati, G., Almasio, P., Nevens, F., Solinas, A., Mura, D., Brouwer, J., et al. (1997) · Gastroenterology · doi:10.1053/gast.1997.v112.pm9024300 · Cited by 1,399
Kiyosawa, K., Sodeyama, T., Tanaka, E., Gibo, Y., Yoshizawa, K., Nakano, Y., Furuta, S., Akahane, Y., Nishioka, K., Purcell, R. H., et al. (1990) · Hepatology · doi:10.1002/hep.1840120409 · Cited by 1,217
Self-citationClinical Outcomes after Transfusion-Associated Hepatitis C
Tong, M. J., El-Farra, N. S., Reikes, A. R., & Co, R. L. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506013322202 · Cited by 1,198
[Gastric adenocarcinoma and kidney transplantation].
Barrio, J., García-Bengoechea, M., Emparanza, J. I., & Arenas, J. I. (1998) · PubMed · Cited by 1,132
Yoshida, H., Shiratori, Y., Moriyama, M., Arakawa, Y., Ide, T., Sata, M., Inoue, O., Yano, M., Tanaka, M., Fujiyama, S., et al. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-3-199908030-00003 · Cited by 1,096
Cited by
Diagnosis, management, and treatment of hepatitis C: An update # † ‡
Ghany, M. G., Strader, D. B., Thomas, D. L., & Seeff, L. B. (2009) · Hepatology · doi:10.1002/hep.22759 · Cited by 2,973
Self-citationRobust hepatitis C virus infection in vitro
Zhong, J., Gastaminza, P., Cheng, G., Kapadia, S., Kato, T., Burton, D. R., Wieland, S. F., Uprichard, S. L., Wakita, T., & Chisari, F. V. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503596102 · Cited by 1,709
Highly Permissive Cell Lines for Subgenomic and Genomic Hepatitis C Virus RNA Replication
Blight, K. J., McKeating, J. A., & Rice, C. M. (2002) · Journal of Virology · doi:10.1128/jvi.76.24.13001-13014.2002 · Cited by 1,193
Course and outcome of hepatitis C
Hoofnagle, J. H. (2002) · Hepatology · doi:10.1002/hep.1840360704 · Cited by 1,084
AASLD practice guidelines: Evaluation of the patient for liver transplantation†
Murray, K. F., & Carithers, R. L. (2005) · Hepatology · doi:10.1002/hep.20704 · Cited by 939
The Natural History of Hepatitis C Virus (HCV) Infection
Chen, S. L., & Morgan, T. R. (2006) · International Journal of Medical Sciences · doi:10.7150/ijms.3.47 · Cited by 860
Treatment of Acute Hepatitis C with Interferon Alfa-2b
Jaeckel, E., Cornberg, M., Wedemeyer, H., Santantonio, T., Mayer, J., Zankel, M., Pastore, G., Dietrich, M., Trautwein, C., & Manns, M. P. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011232 · Cited by 800
Hepatic T cells and liver tolerance
Crispe, I. N. (2003) · Nature Reviews Immunology · doi:10.1038/nri981 · Cited by 661
Perlemuter, G., Sabile, A., Letteron, P., Vona, G., Topilco, A., Chrétien, Y., Koike, K., Pessayre, D., Chapman, J., Barba, G., et al. (2002) · The FASEB Journal · doi:10.1096/fj.01-0396com · Cited by 584
Gerlach, J. T., Diepolder, H. M., Zachoval, R., Gruener, N. H., Jung, M.-C., Ulsenheimer, A., Schraut, W. W., Schirren, C. A., Waechtler, M., Backmund, M., et al. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00668-1 · Cited by 524
Dreux, M., Garaigorta, U., Boyd, B., Décembre, E., Chung, J., Whitten-Bauer, C., Wieland, S., & Chisari, F. V. (2012) · Cell Host & Microbe · doi:10.1016/j.chom.2012.08.010 · Cited by 475
Farci, P. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00051-x · Cited by 467
The global burden of disease attributable to contaminated injections given in health care settings
Hauri, A. M., Armstrong, G. L., & Hutin, Y. J. F. (2004) · International Journal of STD & AIDS · doi:10.1258/095646204322637182 · Cited by 458
Effect of Alpha Interferon on the Hepatitis C Virus Replicon
Guo, J.-T., Bichko, V. V., & Seeger, C. (2001) · Journal of Virology · doi:10.1128/jvi.75.18.8516-8523.2001 · Cited by 443
DNA Microarray Analysis of Chimpanzee Liver during Acute Resolving Hepatitis C Virus Infection
Bigger, C. B., Brasky, K. M., & Lanford, R. E. (2001) · Journal of Virology · doi:10.1128/jvi.75.15.7059-7066.2001 · Cited by 442
American Gastroenterological Association Technical Review on the Management of Hepatitis C
Dienstag, J. L., & McHutchison, J. G. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.010 · Cited by 384
DC-SIGN and L-SIGN Are High Affinity Binding Receptors for Hepatitis C Virus Glycoprotein E2
Lozach, P.-Y., Lortat-Jacob, H., De Lacroix De Lavalette, A., Staropoli, I., Foung, S., Amara, A., Houlès, C., Fieschi, F., Schwartz, O., Virelizier, J.-L., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301284200 · Cited by 375
Epidemiology and natural history of hepatocellular carcinoma
McGlynn, K. A., & London, W. T. (2005) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2004.10.004 · Cited by 373
Prospects for a vaccine against the hepatitis C virus
Houghton, M., & Abrignani, S. (2005) · Nature · doi:10.1038/nature04081 · Cited by 312
RNA Viruses: ROS-Mediated Cell Death
Reshi, M. L., Su, Y.-C., & Hong, J.-R. (2014) · International Journal of Cell Biology · doi:10.1155/2014/467452 · Cited by 305
Depression During Pegylated Interferon-Alpha Plus Ribavirin Therapy: Prevalence and Prediction
Raison, C. L., Borisov, A. S., Broadwell, S. D., Capuron, L., Woolwine, B. J., Jacobson, I. M., Nemeroff, C. B., & Miller, A. H. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0106 · Cited by 299
Maheshwari, A., Ray, S., & Thuluvath, P. J. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61116-2 · Cited by 295
In Vitro Resistance Studies of Hepatitis C Virus Serine Protease Inhibitors, VX-950 and BILN 2061
Lin, C., Lin, K., Luong, Y.-P., Rao, B. G., Wei, Y.-Y., Brennan, D. L., Fulghum, J. R., Hsiao, H.-M., Ma, S., Maxwell, J. P., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313020200 · Cited by 288
Jiang, D., Guo, H., Xu, C., Chang, J., Gu, B., Wang, L., Block, T. M., & Guo, J.-T. (2008) · Journal of Virology · doi:10.1128/jvi.02113-07 · Cited by 288
KIR and disease: a model system or system of models?
Khakoo, S. I., & Carrington, M. (2006) · Immunological Reviews · doi:10.1111/j.1600-065x.2006.00459.x · Cited by 280
(2003) · PsycEXTRA Dataset · doi:10.1037/e545982006-001 · Cited by 280
Rushbrook, S. M., Ward, S. M., Unitt, E., Vowler, S. L., Lucas, M., Klenerman, P., & Alexander, G. J. M. (2005) · Journal of Virology · doi:10.1128/jvi.79.12.7852-7859.2005 · Cited by 275
Fibrosis and disease progression in hepatitis C
Marcellin, P., Asselah, T., & Boyer, N. (2002) · Hepatology · doi:10.1002/hep.1840360707 · Cited by 267
Njoroge, F. G., Chen, K. X., Shih, N.-Y., & Piwinski, J. J. (2008) · Accounts of Chemical Research · doi:10.1021/ar700109k · Cited by 266
Intrahepatic Gene Expression during Chronic Hepatitis C Virus Infection in Chimpanzees
Bigger, C. B., Guerra, B., Brasky, K. M., Hubbard, G., Beard, M. R., Luxon, B. A., Lemon, S. M., & Lanford, R. E. (2004) · Journal of Virology · doi:10.1128/jvi.78.24.13779-13792.2004 · Cited by 259
The natural history of recurrent hepatitis C and what influences this
Gane, E. J. (2008) · Liver Transplantation · doi:10.1002/lt.21646 · Cited by 255
Hepatitis C virus infection and insulin resistance
Bose, S. K. (2014) · World J Diabetes · doi:10.4239/wjd.v5.i1.52 · Cited by 118
Etiology of Liver Cirrhosis in Mexico
Méndez-Sánchez, N., Aguilar-Ramírez, J. R., Reyes, A., Dehesa, M., Juárez, A., Castañeda, B., Sánchez-Avila, F., Poo, J. L., Guevara González, L., Lizardi, J., et al. (2004) · Annals of Hepatology · doi:10.1016/s1665-2681(19)32122-2 · Cited by 106
“com complications of chronic hepatitis C infection are cirrhosis, end-stage liver disease, and hepatocellular carcinoma, which develop in a proportion of patients after many years or decades of infection.(19,20) Progression to cirrhosis is often clinically silent, and some patients are not known to have hepatitis C un…”
Chua, B. Y., Eriksson, E. M., Brown, L. E., Zeng, W., Gowans, E. J., Torresi, J., & Jackson, D. C. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.03.032 · Cited by 54
Metadata
- Authors
- Alter, H. J., & Seeff, L. B.
- Venue
- Seminars in Liver Disease
- Publisher
- Georg Thieme Verlag KG
- Published
- 2000
- Volume
- Volume 20
- Issue
- Number 01
- Pages
- 0017-0036
- ISSN
- 0272-8087 (ISSN-L)
- 1098-8971
- OpenAlex
- W2020004919
- Cited by
- 736
- References
- 61
- FWCI
- 22.88
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.